Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-01-10 | Amended | $2,890,724 | $1,345,724 | Debt Only | 06b | SEC link |
| 2024-01-11 | Amended | $1,545,000 | $645,000 | Debt Only | 06b | SEC link |
| 2023-02-22 | New | $900,000 | $900,000 | Debt Only | 06b | SEC link |
| 2021-03-24 | New | $275,005 | $275,005 | Equity Only | 06b | SEC link |
| 2017-10-26 | Amended | $1,160,000 | $300,000 | Debt Only | 06b | SEC link |
| 2017-08-31 | New | $860,000 | $860,000 | Debt Only | 06b | SEC link |
| 2015-09-03 | New | $576,504 | $576,504 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Clay Anselmo | Director |
| Jeffrey Chambers | Director |
| Bruce Faulken | Director |
| Steven Healy | Director |
| James Ness | Executive |
| John Schorgl | Director, Executive, Promoter |
| Craig Walker | Director |